by jen@juniper-point.com | Jan 29, 2025
In January 2025, Ms. Gulfo was appointed to the Board of Directors. She brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world’s best-selling medicines at...
by amyconrad | May 7, 2024
Dr. Rothenberg is a trained oncologist who brings two decades of clinical care and drug development experience across multiple therapeutic modalities to the TYRA board spanning target identification through approval. Dr. Rothenberg currently serves as the Chief...
by amyconrad | May 7, 2024
Dr. Moran has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as overseeing NDA and MAA submissions for various investigational products, including the successful approval of Nerlynx. Dr. Moran...
by tyraadmin | Jun 11, 2021
Rehan Verjee has served as a member of our Board since June 2021. Mr. Verjee is currently the founding CEO of Precede Biosciences, a venture-backed, liquid-biopsy diagnostic company. Prior to founding Precede Biosciences, Mr. Verjee was a member of the Healthcare...
by tyraadmin | Jun 11, 2021
Todd Harris is Chief Executive Officer of Tyra which he co-founded in August 2018. Prior to co-founding Tyra, Todd co-founded Sienna Biopharmaceuticals, Inc. (SNNA) a clinical-stage biopharmaceutical company where he was Chief Executive Officer and a member of the...
